Vectus Biosystems Limited (AU:VBS)
ASX:VBS
Top Page
Vectus Biosystems Limited
(Sydney:VBS)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.15
▼(-17.78% Downside)
Action:UpgradedDate:03/24/26
The score is held back primarily by weak financial performance—shrinking revenue, persistent losses, ongoing cash burn, and negative equity—raising financing and sustainability risk. Technical indicators are moderately supportive with the price above key moving averages and positive momentum signals, but extremes (stochastic at 100) reduce confidence. Valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
High gross margin profile
Vectus reports a consistently very high gross margin profile, which is a durable commercial strength: when products or licenses scale, high gross margins enable rapid operating leverage and healthier profitability per product, supporting sustainable margins once fixed R&D and SG&A are covered.
Negative Factors
Shrinking revenue
A 45.9% YoY revenue decline is a durable red flag for commercial traction and cash runway. Falling top-line reduces internal funding for trials and makes licensing or partnership negotiations harder, forcing reliance on external financing which can dilute stakeholders and slow strategic progress.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin profile
Vectus reports a consistently very high gross margin profile, which is a durable commercial strength: when products or licenses scale, high gross margins enable rapid operating leverage and healthier profitability per product, supporting sustainable margins once fixed R&D and SG&A are covered.
Read all positive factors
Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$8.02M
Dividend YieldN/A
Average Volume (3M)97.35K
Price to Earnings (P/E)―
Beta (1Y)0.15
Revenue GrowthN/A
EPS Growth24.09%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding53,433,330
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vectus Biosystems Limited Business Overview & Revenue Model
Company Description
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead ...
Vectus Biosystems Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
17
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.47K | 478.18K | 1.14M | 1.35M | 1.30M | 180.00 |
| Gross Profit | 82.89K | 478.18K | 1.14M | 1.31M | 1.28M | 1.02M |
| EBITDA | -1.39M | -1.69M | -2.27M | -3.19M | -3.28M | -3.71M |
| Net Income | -1.41M | -1.78M | -2.34M | -3.45M | -3.99M | -3.86M |
Balance Sheet | ||||||
| Total Assets | 461.65K | 782.66K | 2.03M | 4.63M | 3.94M | 6.98M |
| Cash, Cash Equivalents and Short-Term Investments | 330.50K | 250.99K | 808.97K | 2.95M | 1.28M | 5.78M |
| Total Debt | 467.10K | 200.00K | 28.93K | 70.21K | 6.90M | 8.68M |
| Total Liabilities | 1.27M | 1.04M | 539.26K | 1.11M | 8.36M | 9.88M |
| Stockholders Equity | -806.29K | -256.62K | 1.49M | 3.52M | -4.42M | -2.90M |
Cash Flow | ||||||
| Free Cash Flow | -830.47K | -830.09K | -2.10M | -2.37M | -4.46M | -3.26M |
| Operating Cash Flow | -830.47K | -830.09K | -2.03M | -2.35M | -4.44M | -3.26M |
| Investing Cash Flow | -70.00K | 101.03K | -67.90K | -17.13K | -21.00K | 0.00 |
| Financing Cash Flow | 421.07K | 171.07K | -41.28K | 4.04M | -34.55K | 6.35M |
Vectus Biosystems Limited Technical Analysis
Positive
0.18
Price Trends
0.14
Positive
0.16
Negative
0.11
Positive
Market Momentum
<0.01
Negative
61.96
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.14, and above the 200-day MA of 0.11, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.96 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VBS.
Vectus Biosystems Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$13.12M | -1.00 | -218.76% | ― | ― | ― | |
47 Neutral | AU$8.02M | -3.28 | 265.12% | ― | ― | 24.09% | |
46 Neutral | AU$6.75M | -1.22 | -119.12% | ― | ― | 87.88% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
40 Underperform | AU$2.84M | -1.64 | -109.45% | ― | ― | 1.03% | |
40 Underperform | AU$2.17M | -4.31 | -32.19% | ― | ― | 46.43% |
* Healthcare Sector Average
AU:VBS
Vectus Biosystems Limited
0.15
0.07
97.37%
AU:BIT
Biotron
―
―
―
AU:CMB
Regeneus Ltd.
0.48
0.16
50.00%
AU:1AD
AdAlta Ltd.
―
―
―
AU:ANR
Anatara Lifesciences Ltd
0.01
>-0.01
-9.09%
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
Vectus Biosystems Limited Corporate Events
Vectus Biosystems Narrows Loss But Net Tangible Assets Turn Negative
Feb 26, 2026
Vectus Biosystems reported a sharp decline in income from ordinary activities for the half year ended 31 December 2025, with revenue falling 99% to just $5,488. The company also posted a net loss attributable to members of $731,694, a 33% improvem...
Vectus Biosystems Nears VB4-P5 Sale to XORTX and Ramps Up Licensing Push
Jan 30, 2026
Vectus Biosystems has moved closer to monetising part of its pipeline, nearing completion of a binding deal to sell its VB4-P5 renal small molecule compound for renal fibrosis to Canadian biotech XORTX Therapeutics for US$3 million in shares and p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.